Category: atopic dermatitis

Upadacitinib was found to be an effective treatment for hand eczema in patients with atopic dermatitis (AD) in a 16 week study.

Atopic dermatitis (AD) severity is associated with incremental societal costs in Sweden. Both direct and indirect costs are higher in patients with mild-to-moderate and severe AD than those without AD.

According to a new study, topical calcineurin inhibitors such as pimecrolimus and tacrolimus did not increase cancer risk in atopic dermatitis (AD) patients.

A recent study has shown that atopic dermatitis (AD) and bacterial skin infection rates are higher in Indigenous youth compared to their non-Indigenous peers in high-income countries.

A recent study found that adult and pediatric atopic dermatitis (AD) patients experienced more adverse effects after prolonged use of corticosteroids.

Tralokinumab treatment in patients with moderate-to-severe atopic dermatitis (AD) does not increase Covid-19 severity or interfere with Covid-19 vaccinations, according to a new study.

A digitally delivered intervention showed significant improvements in treatment adherence and other clinical outcomes in atopic dermatitis (AD) patients, according to a new study.

New research has identified an immune biomarker in newborns that may predict the onset and severity of pediatric atopic dermatitis (AD).

According to a recent study, photoaggravated atopic dermatitis (PAD) severely impacts quality of life for patients. 

According to a recent study, children are more likely to have atopic dermatitis (AD) in the first two years of life if their parents have AD or asthma.